In the US, Edoxaban (edoxaban systemic) is a member of the drug class factor Xa inhibitors and is used to treat Atrial Fibrillation, Deep Vein Thrombosis, Prevention of Thromboembolism in Atrial Fibrillation and Pulmonary Embolism.
CAS registry number (Chemical Abstracts Service)
- Edoxabanum (Latin)
- Edoxaban (German)
- Édoxaban (French)
- Edoxabán (Spanish)
- Edoxaban (OS: USAN)
- DU-176 (IS)
- UNII-NDU3J18APO (IS)
- Edoxaban Tosilate Hydrate (OS: JAN)
- Edoxaban Tosylate (OS: USAN)
- DU-176b (IS)
- UNII-32W99UE810 (IS)
Daiichi Sankyo, Japan; Daiichi Sankyo, Switzerland; Daiichi Sankyo, Germany; Daiichi Sankyo UK, United Kingdom
Daiichi Sankyo, United States
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.